| Literature DB >> 25176217 |
Zheng Zheng1, Han-zhong Li1, Yong-qiang Li1.
Abstract
Since 2006, tyrosine kinase inhibitors and anti-angiogenic drugs have revolutionized the treatment of metastatic renal cell carcinoma by improving progression-free survival and overall survival. The prognostic factors in metastatic renal cell carcinoma treated by targeted therapy include anatomical, histological, clinical, biological, and molecular parameters. The accuracy of these prognostic factors are not high when applied alone. A renal cancer prognostic system that combines all these prognostic factors can improve the risk assessment of renal cancer and prognosis prediction, and thus guide clinical decision-making.Entities:
Mesh:
Year: 2014 PMID: 25176217 DOI: 10.3881/j.issn.1000-503X.2014.04.018
Source DB: PubMed Journal: Zhongguo Yi Xue Ke Xue Yuan Xue Bao ISSN: 1000-503X